<?xml version='1.0' encoding='utf-8'?>
<document id="19349522"><sentence text="Renal organic anion transporter-mediated drug-drug interaction between gemcabene and quinapril."><entity charOffset="85-94" id="DDI-PubMed.19349522.s1.e0" text="quinapril" /></sentence><sentence text="In humans and rats, a synergistic blood pressure reduction was observed when the fibrate gemcabene (CI-1027) was coadministered with the angiotensin-converting enzyme inhibitor quinapril"><entity charOffset="81-98" id="DDI-PubMed.19349522.s2.e0" text="fibrate gemcabene" /><entity charOffset="100-107" id="DDI-PubMed.19349522.s2.e1" text="CI-1027" /><entity charOffset="137-148" id="DDI-PubMed.19349522.s2.e2" text="angiotensin" /><entity charOffset="177-186" id="DDI-PubMed.19349522.s2.e3" text="quinapril" /><pair ddi="false" e1="DDI-PubMed.19349522.s2.e0" e2="DDI-PubMed.19349522.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19349522.s2.e0" e2="DDI-PubMed.19349522.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19349522.s2.e0" e2="DDI-PubMed.19349522.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19349522.s2.e0" e2="DDI-PubMed.19349522.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19349522.s2.e1" e2="DDI-PubMed.19349522.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19349522.s2.e1" e2="DDI-PubMed.19349522.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19349522.s2.e1" e2="DDI-PubMed.19349522.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19349522.s2.e2" e2="DDI-PubMed.19349522.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19349522.s2.e2" e2="DDI-PubMed.19349522.s2.e3" /></sentence><sentence text=" In a quinapril (3 mg/kg) pharmacokinetic rat study, there was a 40% decrease in urinary excretion and a 53% increase in plasma area under the curve from 0 to 24 h of the active metabolite quinaprilat when coadministered with gemcabene (30 mg/kg)"><entity charOffset="6-15" id="DDI-PubMed.19349522.s3.e0" text="quinapril" /><entity charOffset="226-235" id="DDI-PubMed.19349522.s3.e1" text="gemcabene" /><pair ddi="false" e1="DDI-PubMed.19349522.s3.e0" e2="DDI-PubMed.19349522.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19349522.s3.e0" e2="DDI-PubMed.19349522.s3.e1" /></sentence><sentence text=" This observation revealed a possible transporter-mediated drug-drug interaction (DDI) between gemcabene and quinapril"><entity charOffset="109-118" id="DDI-PubMed.19349522.s4.e0" text="quinapril" /></sentence><sentence text=" This led to a series of studies investigating the underlying clearance mechanisms associated with these compounds intended to elucidate renal transporter interactions between quinapril and gemcabene"><entity charOffset="176-185" id="DDI-PubMed.19349522.s5.e0" text="quinapril" /><entity charOffset="190-199" id="DDI-PubMed.19349522.s5.e1" text="gemcabene" /><pair ddi="false" e1="DDI-PubMed.19349522.s5.e0" e2="DDI-PubMed.19349522.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19349522.s5.e0" e2="DDI-PubMed.19349522.s5.e1" /></sentence><sentence text=" In vitro transporter studies using human embryonic kidney 293 cells transfected with human or rat organic anion transporter 3 (hOAT3, rOat3) revealed that quinaprilat is a substrate in both species, with a K(m) value of 13" /><sentence text="4 microM for hOAT3" /><sentence text=" Subsequent studies discovered that gemcabene inhibited quinaprilat uptake by hOAT3 and rOat3 at IC(50) values of 35 and 48 microM, respectively" /><sentence text=" Moreover, gemcabene acylglucuronide, the major metabolite of gemcabene glucuronidation, also inhibited hOAT3- and rOat3-mediated uptake of quinaprilat at IC(50) values of 197 and 133 microM, respectively"><entity charOffset="11-36" id="DDI-PubMed.19349522.s9.e0" text="gemcabene acylglucuronide" /><entity charOffset="62-71" id="DDI-PubMed.19349522.s9.e1" text="gemcabene" /><pair ddi="false" e1="DDI-PubMed.19349522.s9.e0" e2="DDI-PubMed.19349522.s9.e0" /><pair ddi="false" e1="DDI-PubMed.19349522.s9.e0" e2="DDI-PubMed.19349522.s9.e1" /></sentence><sentence text=" High plasma concentrations of gemcabene (&gt;100 microM) achieved in humans and rats upon oral dosing corroborate with gemcabene inhibition of renal OAT3-mediated secretion of quinaprilat in vitro"><entity charOffset="31-40" id="DDI-PubMed.19349522.s10.e0" text="gemcabene" /><entity charOffset="117-126" id="DDI-PubMed.19349522.s10.e1" text="gemcabene" /><pair ddi="false" e1="DDI-PubMed.19349522.s10.e0" e2="DDI-PubMed.19349522.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19349522.s10.e0" e2="DDI-PubMed.19349522.s10.e1" /></sentence><sentence text=" This investigation established that a DDI between gemcabene and quinapril involving inhibition of renal transporters and subsequent elevation in plasma concentrations of quinaprilat is responsible for the apparent synergistic blood pressure reduction observed with these compounds"><entity charOffset="51-60" id="DDI-PubMed.19349522.s11.e0" text="gemcabene" /><entity charOffset="65-74" id="DDI-PubMed.19349522.s11.e1" text="quinapril" /><entity charOffset="171-182" id="DDI-PubMed.19349522.s11.e2" text="quinaprilat" /><pair ddi="false" e1="DDI-PubMed.19349522.s11.e0" e2="DDI-PubMed.19349522.s11.e0" /><pair ddi="false" e1="DDI-PubMed.19349522.s11.e0" e2="DDI-PubMed.19349522.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19349522.s11.e0" e2="DDI-PubMed.19349522.s11.e2" /><pair ddi="false" e1="DDI-PubMed.19349522.s11.e1" e2="DDI-PubMed.19349522.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19349522.s11.e1" e2="DDI-PubMed.19349522.s11.e2" /></sentence><sentence text="" /></document>